- Clinical Interests
- Scleroderma/Systemic sclerosis
- Connective tissue associated interstitial lung disease
- Raynaud's phenomenon
- Rheumatoid arthritis
- Medical Education
- MD, SUNY at Syracuse (Upstate) College of Medicine
- Residency, Northwestern Memorial Hospital
- Fellowship, Massachusetts General Hospital
- Board Certifications
- Boston: Massachusetts General Hospital
- Waltham: Mass General Waltham
- Existing Patients
- Patient Gateway
- Insurances Accepted
- Aetna Health Inc.
- AllWays Health (NHP) - ACD
- AllWays Health (NHP) - PBO
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
- Provider Gender
Dr. Flavia Castelino is the Director of the Scleroderma Program at Massachusetts General Hospital and Assistant Professor of Medicine at Harvard Medical School. She is a board-certified physician in the Division of Rheumatology and she specializes in the treatment of scleroderma and connective tissue disease-associated lung disease.
Her research focuses on the role of lipid mediators in scleroderma fibrosis. Dr. Castelino is a member of the Early Career Investigator Subcommittee of the American College of Rheumatology and the Scleroderma Clinical Trials Consortium. She acts as a reviewer for multiple rheumatology journals including Arthritis and Rheumatology, Arthritis Care and Research and Arthritis Research and Therapy. She is the recipient of numerous awards including the American College of Rheumatology Physician-Scientist Development Award and the Scleroderma Foundation Walter A. Coyle Memorial Research Award. Recently, she was awarded a National Institute of Health research grant to study the role of a lipid mediator, lysophosphatidic acid in scleroderma fibrosis.
- Research Summary
Clinical Studies at the MGH Scleroderma Program
- Prospective Registry In Scleroderma at MGH (PRISM)- Database and bio-repository of patients with scleroderma seen at the MGH Scleroderma Program.
- Lysophosphatidic Acid (LPA) as a Biomarker in Scleroderma- Evaluate whether LPA levels in the blood and skin can help us understand disease progression in scleroderma.
- MRI to Evaluate Vascular Abnormalities in Scleroderma- Use of hand MRI to determine whether vascular (blood vessel) abnormalities are an early finding in scleroderma.
- Abatacept Systemic Sclerosis Trial (ASSET, Phase II trial)- Evaluate the treatment of Abatacept in patients with diffuse scleroderma.
- Prospective Registry in Early Systemic Sclerosis (PRESS)- A collaborative, multi-center database of patients in the early stages of scleroderma.
- Scleroderma Clinical Trials Consortium (SCTC) Calcinosis Working Group- A collaborative, multi-center database of patients with scleroderma and calcinosis.
For further information, please contact: Ana Fernandes (firstname.lastname@example.org, 617-724-2792)
- Schoenfeld SR, Castelino FV. Evaluation and management approaches for scleroderma lung disease. Ther Adv Resp Dis. 2017 Jun 1.
- Castelino FV, Bain G, Pace VA, Black KE, George L, Probst CK, Goulet L, Lafyatis R, Tager AM. An Autotaxin-LPA-IL-6 Amplification Loop Drives Scleroderma Fibrosis. Arthritis Rheumatol. 2016 Dec;68(12):2964-2974
- Castelino FV, Varga J. Emerging cellular and molecular targets in fibrosis: implications for scleroderma pathogenesis and targeted therapy. Curr Opin Rheum 2014 Nov;26(6):607-14
- Castelino FV, Varga J. Current Status of Systemic Sclerosis Biomarkers. Expert Rev Clin Immunol, 2013 Nov; 9 (11):1077-90.
- Castelino FV. Lipids and Eicosanoids in Fibrosis: Emerging Targets for Therapy. Curr Op Rheum 2012; 24 (6): 649-655.
- Castelino FV, Goldberg H, Dellaripa PF. The Impact of Rheumatologic Evaluation in the Management of Patients with Interstitial Lung Disease. Rheumatology 2011 Mar;50(3):489-93.
- Castelino FV, Seiders J, Bain G, Brooks SF, King C, Swaney J, Lorrain D, Chun J, Luster AD, Tager AM. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthritis and Rheumatism, 2011. May; 63(5):1405-15.
55 Fruit Street
Boston, MA 02114-2696
52 Second Avenue
Waltham, MA 02451-1155